Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review

BACKGROUND: Female patients undergoing anticancer treatment are at elevated risk of adverse ovarian outcomes including infertility and premature ovarian insufficiency (POI), which is associated with short- and long-term health risks. Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Richard A, Cameron, David, Clatot, Florian, Demeestere, Isabelle, Lambertini, Matteo, Nelson, Scott M, Peccatori, Fedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071067/
https://www.ncbi.nlm.nih.gov/pubmed/35199161
http://dx.doi.org/10.1093/humupd/dmac004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071067/
https://www.ncbi.nlm.nih.gov/pubmed/35199161
http://dx.doi.org/10.1093/humupd/dmac004

Ejemplares similares